Pipeline
Pipeline
Pipeline
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Pipeline: Internal Innovaton are External Partnerships
Pipeline: Internal Innovaton are External Partnerships
Asset
Indication
Target
Lead Identification
Optimization
IND enabling
QUM1
QUM1
Autoimmune diseases (RA,MG), B cell lymphoma
Autoimmune diseases (RA,MG), B cell lymphoma
Autoimmune diseases (RA,MG), B cell lymphoma
Indication
CD19 x Q²TCE
CD19 x Q²TCE
CD19 x Q²TCE
Target
Lead
identification
Optimization
QUM2
collaboarion Program1
Small Cell Lung Cancer (SCLC)
Indication
CD19 x Q²TCE
Target
Lead
identification
Optimization
RQ
collaboarion Program2
Heapatocellular carcinoma (HCC)
Indication
Novel target (Undisclosed) Q²TCE
Target
Lead
identification
Optimization
QUM3
Prostate Cancer
Indication
PSMA x Q²TCE
Target
Lead
identification
Optimization
QUM4
Acute Myeloid Leukemia(AML)
Indication
CLL1 x Q²TCE
Target
Lead
identification
Optimization
QUM5
collaboarion Program3
Undisclosed
Indication
Undisclosed Q²TCE
Target
Lead
identification
Optimization
QUM2
collaboarion Program1
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)
DLL3 x Q²TCE
DLL3 x Q²TCE
RQ
collaboarion Program2
Heapatocellular carcinoma (HCC)
Heapatocellular carcinoma (HCC)
Undisclosed Q²TCE
Novel target (Undisclosed) Q²TCE
QUM3
Prostate Cancer
Prostate Cancer
Undisclosed Q²TCE
Undisclosed Q²TCE
QUM4
Acute Myeloid Leukemia(AML)
Acute Myeloid Leukemia(AML)
Undisclosed Q²TCE
Undisclosed Q²TCE
Undisclosed
Undisclosed
Undisclosed Q²TCE
Undisclosed Q²TCE
